公开(公告)号：US12115230B2

公开(公告)日：2024-10-15

申请号：US17918092

申请日：2021-04-09

申请人： Verve Therapautics, Inc.

发明人： Alexandra Chadwick ,  Kallanthottathil G. Rajeev ,  Ellen Rohde ,  Christopher Cheng ,  Caroline Reiss

IPC分类号： C12N15/11 ,  A61K9/127 ,  A61K31/7105 ,  A61K38/46 ,  A61K48/00 ,  C07K14/515 ,  C12N9/22 ,  C12N15/113 ,  C12N15/90

CPC分类号： A61K48/0066 ,  A61K9/127 ,  A61K31/7105 ,  A61K38/465 ,  C07K14/515 ,  C12N9/22 ,  C12N15/11 ,  C12N15/113 ,  C12N15/907 ,  C07K2319/09 ,  C07K2319/80 ,  C12N2310/20 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/331 ,  C12N2310/335 ,  C12N2310/344 ,  C12N2310/3521 ,  C12N2800/80

摘要： Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.

公开(公告)号：US20230340435A1

公开(公告)日：2023-10-26

申请号：US17918092

申请日：2021-04-09

申请人： Verve Therapautics, Inc.

发明人： Alexandra Chadwick ,  Kallanthottathil G. Rajeev ,  Ellen Rohde ,  Christopher Cheng ,  Caroline Reiss

IPC分类号： C12N9/22 ,  C12N15/11 ,  C12N15/90 ,  A61K38/46 ,  A61K31/7105

CPC分类号： C12N9/22 ,  A61K31/7105 ,  A61K38/465 ,  C12N15/11 ,  C12N15/907 ,  C07K2319/09 ,  C07K2319/80 ,  C12N2310/20 ,  C12N2310/321

摘要： Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.